Scholars@Duke

• Background
• 

  Education, Training, & Certifications

  • Resident, Medicine, University of California - Irvine 1997 - 1999
  • Fellow, Hematology, Oncology, The University of Chicago 1993 - 1997
  • Resident, National University Hospital (Singapore) 1991 - 1993
  • M.B.B.Ch., University of Cambridge (United Kingdom) 1987
• 

  Previous Appointments & Affiliations

  • Associate Professor of Medicine, Medicine, Medical Oncology, Medicine 2010 - 2020
• Research
• 

  External Relationships

  • Accelerate Technologies, AUM Biosciences.
  • American Society of Hematology
  • European Hematology Association
• Publications & Artistic Works
• 

  Selected Publications

  • Academic Articles

    • Lee, Kian Leong, Tun Kiat Ko, Nicole Y. L. Saw, Asif Javed, Axel M. Hillmer, Charles Chuah, Vaidehi Krishnan, and S Tiong Ong. “Validation and refinement of a RUNX1 mutation-associated gene expression signature in blast crisis chronic myeloid leukemia.” Leukemia 36, no. 3 (March 2022): 892–96. https://doi.org/10.1038/s41375-022-01508-1.
       Full Text  Link to Item
    • Krishnan, Vaidehi, Dennis Dong Hwan Kim, Timothy P. Hughes, Susan Branford, and S Tiong Ong. “Integrating genetic and epigenetic factors in chronic myeloid leukemia risk assessment: toward gene expression-based biomarkers.” Haematologica 107, no. 2 (February 1, 2022): 358–70. https://doi.org/10.3324/haematol.2021.279317.
       Full Text  Link to Item
    • Shyamsunder, Pavithra, Shree Pooja Sridharan, Vikas Madan, Pushkar Dakle, Cao Zeya, Deepika Kanojia, Wee-Joo Chng, S Tiong Ong, and H Phillip Koeffler. “THZ531 Induces a State of BRCAness in Multiple Myeloma Cells: Synthetic Lethality with Combination Treatment of THZ 531 with DNA Repair Inhibitors.” Int J Mol Sci 23, no. 3 (January 21, 2022). https://doi.org/10.3390/ijms23031207.
       Full Text  Link to Item
    • Schmidt, Florian, Bobby Ranjan, Quy Xiao Xuan Lin, Vaidehi Krishnan, Ignasius Joanito, Mohammad Amin Honardoost, Zahid Nawaz, et al. “RCA2: a scalable supervised clustering algorithm that reduces batch effects in scRNA-seq data.” Nucleic Acids Res 49, no. 15 (September 7, 2021): 8505–19. https://doi.org/10.1093/nar/gkab632.
       Full Text  Link to Item
    • Sinnakannu, Joanna R., Kian Leong Lee, Shanshan Cheng, Jia Li, Mengge Yu, Siew Peng Tan, Clara Chong Hui Ong, et al. “SRSF1 mediates cytokine-induced impaired imatinib sensitivity in chronic myeloid leukemia.” Leukemia 34, no. 7 (July 2020): 1787–98. https://doi.org/10.1038/s41375-020-0732-1.
       Full Text  Link to Item
    • Ko, Tun Kiat, Asif Javed, Kian Leong Lee, Thushangi N. Pathiraja, Xingliang Liu, Simeen Malik, Sheila Xinxuan Soh, et al. “An integrative model of pathway convergence in genetically heterogeneous blast crisis chronic myeloid leukemia.” Blood 135, no. 26 (June 25, 2020): 2337–53. https://doi.org/10.1182/blood.2020004834.
       Full Text  Link to Item
    • Takeuchi, Shinji, Tetsunari Hase, Shinobu Shimizu, Masahiko Ando, Akito Hata, Haruyasu Murakami, Takahiro Kawakami, et al. “Phase I study of vorinostat with gefitinib in BIM deletion polymorphism/epidermal growth factor receptor mutation double-positive lung cancer.” Cancer Sci 111, no. 2 (February 2020): 561–70. https://doi.org/10.1111/cas.14260.
       Full Text  Link to Item
    • Arai, Sachiko, Shinji Takeuchi, Koji Fukuda, Azusa Tanimoto, Akihiro Nishiyama, Hiroaki Konishi, Akimitsu Takagi, Hiroyuki Takahashi, S Tiong Ong, and Seiji Yano. “Resminostat, a histone deacetylase inhibitor, circumvents tolerance to EGFR inhibitors in EGFR-mutated lung cancer cells with BIM deletion polymorphism.” J Med Invest 67, no. 3.4 (2020): 343–50. https://doi.org/10.2152/jmi.67.343.
       Full Text  Link to Item
    • Branford, Susan, Dennis Dong Hwan Kim, Jane F. Apperley, Christopher A. Eide, Satu Mustjoki, S Tiong Ong, Georgios Nteliopoulos, et al. “Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia.” Leukemia 33, no. 8 (August 2019): 1835–50. https://doi.org/10.1038/s41375-019-0512-y.
       Full Text  Link to Item
    • Than, Hein, Weng K. Lye, Colin Sng, John C. Allen, S Tiong Ong, and Charles Chuah. “BIM deletion polymorphism profiling complements prognostic values of risk scores in imatinib-treated Asian chronic myeloid leukemia patients.” Leuk Lymphoma 60, no. 1 (January 2019): 234–37. https://doi.org/10.1080/10428194.2018.1461863.
       Full Text  Link to Item
    • Leidy-Davis, Tiffany, Kai Cheng, Leslie O. Goodwin, Judith L. Morgan, Wen Chun Juan, Xavier Roca, S Tiong Ong, and David E. Bergstrom. “Viable Mice with Extensive Gene Humanization (25-kbp) Created Using Embryonic Stem Cell/Blastocyst and CRISPR/Zygote Injection Approaches.” Sci Rep 8, no. 1 (October 9, 2018): 15028. https://doi.org/10.1038/s41598-018-33408-9.
       Full Text  Link to Item
    • Yang, Haiyan, Lohitha Rao Chennamaneni, Melvyn Wai Tuck Ho, Shi Hua Ang, Eldwin Sum Wai Tan, Duraiswamy Athisayamani Jeyaraj, Yoon Sheng Yeap, et al. “Optimization of Selective Mitogen-Activated Protein Kinase Interacting Kinases 1 and 2 Inhibitors for the Treatment of Blast Crisis Leukemia.” J Med Chem 61, no. 10 (May 24, 2018): 4348–69. https://doi.org/10.1021/acs.jmedchem.7b01714.
       Full Text  Link to Item
    • Ng, King Pan, Aditi Manjeri, Lin Ming Lee, Zhu En Chan, Chin Yee Tan, Qiancheng Darren Tan, A’Qilah Majeed, et al. “The arginase inhibitor Nω-hydroxy-nor-arginine (nor-NOHA) induces apoptosis in leukemic cells specifically under hypoxic conditions but CRISPR/Cas9 excludes arginase 2 (ARG2) as the functional target.” Plos One 13, no. 10 (2018): e0205254. https://doi.org/10.1371/journal.pone.0205254.
       Full Text  Link to Item
    • Liu, Jun, Malini Bhadra, Joanna Rajeswary Sinnakannu, Wan Lin Yue, Cheryl Weiqi Tan, Frank Rigo, S Tiong Ong, and Xavier Roca. “Overcoming imatinib resistance conferred by the BIM deletion polymorphism in chronic myeloid leukemia with splice-switching antisense oligonucleotides.” Oncotarget 8, no. 44 (September 29, 2017): 77567–85. https://doi.org/10.18632/oncotarget.20658.
       Full Text  Link to Item
    • Soh, Sheila X., Fahad J. Siddiqui, John C. Allen, Go Woon Kim, Jae Cheol Lee, Yasushi Yatabe, Manabu Soda, et al. “A systematic review and meta-analysis of individual patient data on the impact of the BIM deletion polymorphism on treatment outcomes in epidermal growth factor receptor mutant lung cancer.” Oncotarget 8, no. 25 (June 20, 2017): 41474–86. https://doi.org/10.18632/oncotarget.17102.
       Full Text  Link to Item
    • Tanimoto, Azusa, Shinji Takeuchi, Sachiko Arai, Koji Fukuda, Tadaaki Yamada, Xavier Roca, S Tiong Ong, and Seiji Yano. “Histone Deacetylase 3 Inhibition Overcomes BIM Deletion Polymorphism-Mediated Osimertinib Resistance in EGFR-Mutant Lung Cancer.” Clin Cancer Res 23, no. 12 (June 15, 2017): 3139–49. https://doi.org/10.1158/1078-0432.CCR-16-2271.
       Full Text  Link to Item
    • Rauzan, Muhammad, Charles T. H. Chuah, Tun Kiat Ko, and S Tiong Ong. “The HDAC inhibitor SB939 overcomes resistance to BCR-ABL kinase Inhibitors conferred by the BIM deletion polymorphism in chronic myeloid leukemia.” Plos One 12, no. 3 (2017): e0174107. https://doi.org/10.1371/journal.pone.0174107.
       Full Text  Link to Item
    • Cherian, Joseph, Kassoum Nacro, Zhi Ying Poh, Samantha Guo, Duraiswamy A. Jeyaraj, Yun Xuan Wong, Melvyn Ho, et al. “Structure-Activity Relationship Studies of Mitogen Activated Protein Kinase Interacting Kinase (MNK) 1 and 2 and BCR-ABL1 Inhibitors Targeting Chronic Myeloid Leukemic Cells.” J Med Chem 59, no. 7 (April 14, 2016): 3063–78. https://doi.org/10.1021/acs.jmedchem.5b01712.
       Full Text  Link to Item
    • Ko, Tun Kiat, Hui San Chin, Charles T. H. Chuah, John W. J. Huang, King-Pan Ng, Seong Lin Khaw, David C. S. Huang, and S Tiong Ong. “The BIM deletion polymorphism: A paradigm of a permissive interaction between germline and acquired TKI resistance factors in chronic myeloid leukemia.” Oncotarget 7, no. 3 (January 19, 2016): 2721–33. https://doi.org/10.18632/oncotarget.5436.
       Full Text  Link to Item
    • Yano, Seiji, Azusa Tanimoto, Shoko Arai, Koji Fukuda, Sin T. Ong, and Shinji Takeuchi. “HDAC Inhibitors Overcome New Generation EGFR-TKI-Resistance Caused by Homozygous BIM Polymorphism in EGFR Mutant Lung Cancer.” Journal of Thoracic Oncology 10, no. 9 (September 1, 2015): S296–97.
       Link to Item
    • Tsai, Becky Pinjou, Judith Jimenez, Sharon Lim, Kerry D. Fitzgerald, Min Zhang, Charles T. H. Chuah, Haley Axelrod, et al. “A novel Bcr-Abl-mTOR-eIF4A axis regulates IRES-mediated translation of LEF-1.” Open Biol 4, no. 11 (November 2014): 140180. https://doi.org/10.1098/rsob.140180.
       Full Text  Link to Item
    • Ko, Tun Kiat, Charles T. H. Chuah, John W. J. Huang, King-Pan Ng, and S Tiong Ong. “The BCL2 inhibitor ABT-199 significantly enhances imatinib-induced cell death in chronic myeloid leukemia progenitors.” Oncotarget 5, no. 19 (October 15, 2014): 9033–38. https://doi.org/10.18632/oncotarget.1925.
       Full Text  Link to Item
    • Ong, S Tiong, Charles T. H. Chuah, Tun Kiat Ko, Axel M. Hillmer, and Wan-Teck Lim. “Reply: the BIM deletion polymorphism cannot account for intrinsic TKI resistance of Chinese individuals with chronic myeloid leukemia.” Nat Med 20, no. 10 (October 2014): 1090–91. https://doi.org/10.1038/nm.3652.
       Full Text  Link to Item
    • Ong, S Tiong. “Heritable resistance to tyrosine kinase inhibitors.” Clin Adv Hematol Oncol 12, no. 7 (July 2014): 454–57.
       Link to Item
    • Juan, Wen Chun, Xavier Roca, and S Tiong Ong. “Identification of cis-acting elements and splicing factors involved in the regulation of BIM Pre-mRNA splicing.” Plos One 9, no. 4 (2014): e95210. https://doi.org/10.1371/journal.pone.0095210.
       Full Text  Link to Item
    • Soh, Sheila Xinxuan, Joshua Yew Suang Lim, John W. J. Huang, Nan Jiang, Allen Eng Juh Yeoh, and S Tiong Ong. “Multi-agent chemotherapy overcomes glucocorticoid resistance conferred by a BIM deletion polymorphism in pediatric acute lymphoblastic leukemia.” Plos One 9, no. 8 (2014): e103435. https://doi.org/10.1371/journal.pone.0103435.
       Full Text  Link to Item
    • Soh, Sheila, and S Tiong Ong. “A novel BIM deletion polymorphism: implications and lessons for cancer targeted therapies.” Rinsho Ketsueki 54, no. 10 (October 2013): 1714–19.
       Link to Item
    • Lim, Sharon, Tzuen Yih Saw, Min Zhang, Matthew R. Janes, Kassoum Nacro, Jeffrey Hill, An Qi Lim, et al. “Targeting of the MNK-eIF4E axis in blast crisis chronic myeloid leukemia inhibits leukemia stem cell function.” Proc Natl Acad Sci U S A 110, no. 25 (June 18, 2013): E2298–2307. https://doi.org/10.1073/pnas.1301838110.
       Full Text  Link to Item
    • Juan, Wen Chun, Tun Kiat Ko, Xavier Roca, and Sin Tiong Ong. “Abstract 4958: Identification of cis-regulatory elements in a BIM deletion polymorphism that regulate splicing and generation of non-apoptotic BIM isoforms.” Cancer Research 72, no. 8_Supplement (April 15, 2012): 4958–4958. https://doi.org/10.1158/1538-7445.am2012-4958.
       Full Text
    • Ng, King Pan, Axel M. Hillmer, Charles T. H. Chuah, Wen Chun Juan, Tun Kiat Ko, Audrey S. M. Teo, Pramila N. Ariyaratne, et al. “A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer.” Nat Med 18, no. 4 (March 18, 2012): 521–28. https://doi.org/10.1038/nm.2713.
       Full Text  Link to Item
    • Juan, Wen Chun, and S Tiong Ong. “The role of protein phosphorylation in therapy resistance and disease progression in chronic myelogenous leukemia.” Prog Mol Biol Transl Sci 106 (2012): 107–42. https://doi.org/10.1016/B978-0-12-396456-4.00007-9.
       Full Text  Link to Item
    • Janes, Matthew R., Jose J. Limon, Lomon So, Jing Chen, Raymond J. Lim, Melissa A. Chavez, Collin Vu, et al. “Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor.” Nat Med 16, no. 2 (February 2010): 205–13. https://doi.org/10.1038/nm.2091.
       Full Text  Link to Item
    • Zhang, Min, Wuxia Fu, Sharmila Prabhu, James C. Moore, Je Ko, Jung Woo Kim, Brian J. Druker, et al. “Inhibition of polysome assembly enhances imatinib activity against chronic myelogenous leukemia and overcomes imatinib resistance.” Mol Cell Biol 28, no. 20 (October 2008): 6496–6509. https://doi.org/10.1128/MCB.00477-08.
       Full Text  Link to Item
    • Arechiga, Adrian F., Bryan D. Bell, Sabrina Leverrier, Brian M. Weist, Melissa Porter, Zhengqi Wu, Yuka Kanno, et al. “A Fas-associated death domain protein/caspase-8-signaling axis promotes S-phase entry and maintains S6 kinase activity in T cells responding to IL-2.” J Immunol 179, no. 8 (October 15, 2007): 5291–5300. https://doi.org/10.4049/jimmunol.179.8.5291.
       Full Text  Link to Item
    • Prabhu, S., D. Saadat, M. Zhang, L. Halbur, J. P. Fruehauf, and S. T. Ong. “A novel mechanism for Bcr-Abl action: Bcr-Abl-mediated induction of the eIF4F translation initiation complex and mRNA translation.” Oncogene 26, no. 8 (February 22, 2007): 1188–1200. https://doi.org/10.1038/sj.onc.1209901.
       Full Text  Link to Item
    • Moore, James C., Carolyn F. Dennehey, Arash Anavim, Kevin M. Kong, and S. Tiong Ong. “Multiple joint effusions associated with high-dose imatinib therapy in a patient with chronic myelogenous leukaemia.” Eur J Haematol 76, no. 5 (May 2006): 444–46. https://doi.org/10.1111/j.1600-0609.2006.00649.x.
       Full Text  Link to Item
    • Ly, Chi, Adrian F. Arechiga, Junia V. Melo, Craig M. Walsh, and S Tiong Ong. “Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin.” Cancer Res 63, no. 18 (September 15, 2003): 5716–22.
       Link to Item
    • Tiong Ong, S., Chi Ly, Mark Nguyen, B. Kay Brightman, and Hung Fan. “Expression profiling of a transformed thymocyte cell line undergoing maturation in vitro identifies multiple genes involved in positive selection.” Cell Immunol 221, no. 1 (January 2003): 64–79. https://doi.org/10.1016/s0008-8749(03)00065-0.
       Full Text  Link to Item
    • Peters, U. R., U. Hasse, E. Oppliger, M. Tschan, S. T. Ong, F. V. Rassool, B. Borisch, A. Tobler, and M. F. Fey. “Aberrant FHIT mRNA transcripts are present in malignant and normal haematopoiesis, but absence of FHIT protein is restricted to leukaemia.” Oncogene 18, no. 1 (January 7, 1999): 79–85. https://doi.org/10.1038/sj.onc.1202256.
       Full Text  Link to Item
    • Ong, S. T., and M. M. Le Beau. “Chromosomal abnormalities and molecular genetics of non-Hodgkin's lymphoma.” Semin Oncol 25, no. 4 (August 1998): 447–60.
       Link to Item
    • Ong, S. T., M. L. Hackbarth, L. C. Degenstein, D. A. Baunoch, J. Anastasi, and T. W. McKeithan. “Lymphadenopathy, splenomegaly, and altered immunoglobulin production in BCL3 transgenic mice.” Oncogene 16, no. 18 (May 7, 1998): 2333–43. https://doi.org/10.1038/sj.onc.1201771.
       Full Text  Link to Item
    • Ong, S. T., K. M. Fong, S. A. Bader, J. D. Minna, M. M. Le Beau, T. W. McKeithan, and F. V. Rassool. “Precise localization of the FHIT gene to the common fragile site at 3p14.2 (FRA3B) and characterization of homozygous deletions within FRA3B that affect FHIT transcription in tumor cell lines.” Genes Chromosomes Cancer 20, no. 1 (September 1997): 16–23. https://doi.org/10.1002/(sici)1098-2264(199709)20:1<16::aid-gcc3>3.0.co;2-c.
       Full Text  Link to Item
    • Fong, K. M., E. J. Biesterveld, A. Virmani, I. Wistuba, Y. Sekido, S. A. Bader, M. Ahmadian, et al. “FHIT and FRA3B 3p14.2 allele loss are common in lung cancer and preneoplastic bronchial lesions and are associated with cancer-related FHIT cDNA splicing aberrations.” Cancer Res 57, no. 11 (June 1, 1997): 2256–67.
       Link to Item
    • Ong, S. T., R. Stupp, and J. E. Ultmann. “The sixth Lugano conference: Basic science papers.” Annals of Oncology 8, no. SUPPL. 2 (January 1, 1997). https://doi.org/10.1093/annonc/8.suppl_2.S1.
       Full Text
    • Ultmann, J. E., S. T. Ong, and R. Stupp. “One and a half decades of the Lugano International Conference on Malignant Lymphoma: variations on a theme or true progress?” Ann Oncol 8 Suppl 1 (1997): 1–3.
       Link to Item
    • Ong, S. T., H. Koeppen, R. A. Larson, and O. I. Olopade. “Successful treatment of angioimmunoblastic lymphadenopathy with dysproteinemia with fludarabine.” Blood 88, no. 6 (September 15, 1996): 2354–55.
       Link to Item
    • Rassool, F. V., M. M. Le Beau, M. L. Shen, M. E. Neilly, R. Espinosa, S. T. Ong, F. Boldog, H. Drabkin, R. McCarroll, and T. W. McKeithan. “Direct cloning of DNA sequences from the common fragile site region at chromosome band 3p14.2.” Genomics 35, no. 1 (July 1, 1996): 109–17. https://doi.org/10.1006/geno.1996.0329.
       Full Text  Link to Item
    • Ong, S. T., and N. J. Vogelzang. “Chemotherapy in malignant pleural mesothelioma. A review.” J Clin Oncol 14, no. 3 (March 1996): 1007–17. https://doi.org/10.1200/JCO.1996.14.3.1007.
       Full Text  Link to Item
    • Ong, S. T., and R. A. Larson. “Current management of acute lymphoblastic leukemia in adults.” Oncology (Williston Park) 9, no. 5 (May 1995): 433–42.
       Link to Item
    • Ultmann, J. E., and S. T. Ong. “The cost-benefit ratio of the cure of Hodgkin's disease.” Cancer J Sci Am 1, no. 1 (May 1995): 23–25.
       Link to Item
    • Ong, S. T., L. J. de Groot, and N. J. Vogelzang. “Phase II evaluation of single agent carboplatin in advanced thyroid carcinoma.” Oncology Reports 1, no. 6 (January 1, 1994): 1217–18.
    • Ong, S. T., and Y. K. Kueh. “Hepatic candidiasis: persistent pyrexia in a patient with acute myeloid leukaemia after recovery from consolidation therapy-induced neutropenia.” Ann Acad Med Singap 22, no. 2 (March 1993): 257–60.
       Link to Item

  • Book Sections

    • Than, H., C. Chuah, and S. T. Ong. “Molecular mechanism of TKI resistance and potential approaches to overcome resistance.” In Molecular Pathogenesis and Treatment of Chronic Myelogenous Leukemia, 167–82, 2015. https://doi.org/10.1007/978-4-431-55714-2_11.
       Full Text

  • Conference Papers

    • Nacro, Kassoum, Joseph Cherian, Haiyan Yang, Yoon Shen Yeap, Zhi Ying Poh, Lohitha Chennamaneni, Shi Hua Ang, et al. “Mnk1/2 and Abl inhibitions for the treatment of blast crisis chronic myelogenous leukemia.” In Abstracts of Papers of the American Chemical Society, Vol. 254. AMER CHEMICAL SOC, 2017.
       Link to Item
    • Ko, Tun Kiat, Xin Xuan Sheila Soh, Willie Yu, Peter S. Winter, Thushangi Pathiraja, Asif Javed, Simeen Malik, et al. “Functional Analysis of the CML Blast Crisis Transcriptome and Epigenome Using Crispr-CAS9 and Pharmacologic Approaches.” In Blood, Vol. 126. AMER SOC HEMATOLOGY, 2015.
       Link to Item
    • Ong, S Tiong, Thushangi Pathiraja, Asif Javed, Xin Xuan Sheila Soh, Simeen Malik, Joanna H. J. Tan, Tun Kiat Ko, et al. “The Genomic and Epigenomic Landscapes of Blast Crisis Transformation in Chronic Myeloid Leukemia.” In Blood, 126:3737–3737. American Society of Hematology, 2015. https://doi.org/10.1182/blood.v126.23.3737.3737.
       Full Text
    • Ng, King Pan, Aditi Manjeri, Kian Leong Lee, Weijie Huang, Soo Yong Tan, Charles T. H. Chuah, Lorenz Poellinger, and S Tiong Ong. “Physiologic hypoxia promotes maintenance of CML stem cells despite effective BCR-ABL1 inhibition.” In Blood, 123:3316–26, 2014. https://doi.org/10.1182/blood-2013-07-511907.
       Full Text  Link to Item
    • Hillmer, Axel M., King-Pan Ng, Charles Chuah, Wen Chun Juan, Tun-Kiat Ko, Audrey S. M. Teo, Pramila N. Ariyaratne, et al. “A Common Deletion Polymorphism in the BIM Gene Contributes to Intrinsic Imatinib Resistance in Chronic Myelogenous Leukemia.” In Blood, 118:724–724. AMER SOC HEMATOLOGY, 2011.
       Link to Item
    • Lim, Sharon, T Yih Saw, Charles Chuah, and S Tiong Ong. “Overexpression and Phosphorylation of eIF4E Is Required for Beta-Catenin Activation in Blast Crisis Chronic Myelogenous Leukemia.” In Blood, 114:22–22. AMER SOC HEMATOLOGY, 2009.
       Link to Item
    • Ng, King-Pan, Tuang Yeow Poh, Wen Tian Sun, Charles Chuah, and S Tiong Ong. “Physiologic Hypoxia Protects Chronic Myelogenous Leukemia Progenitors From Elimination by Imatinib Mesylate.” In Blood, 114:858–858. AMER SOC HEMATOLOGY, 2009.
       Link to Item

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.